Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Decrease in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 13,800 shares, a drop of 34.3% from the January 31st total of 21,000 shares. Based on an average trading volume of 373,100 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.5% of the company’s shares are short sold.

Coeptis Therapeutics Trading Down 1.8 %

Shares of NASDAQ COEP traded down $0.19 during trading on Monday, hitting $10.56. 86,391 shares of the company were exchanged, compared to its average volume of 174,682. The company has a fifty day moving average price of $9.27 and a 200-day moving average price of $5.76. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.40 and a current ratio of 0.40. The firm has a market capitalization of $34.24 million, a PE ratio of -1.82 and a beta of -0.82. Coeptis Therapeutics has a 12-month low of $2.31 and a 12-month high of $13.70.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.